September 23, 2020
Pressao Medical today announced the raising of additional private funding. The new investment will be used to continue product development, leading to a regulatory filing in various countries. The company is part of the portfolio of Adventus Ventures, LLC, a medical incubator and early-stage investor.
Pressao Medical has two products under development. The first is BP-ADJUST™, a new device in the form of a wristwatch that monitors blood pressure (BP) and heart rate and uses the information to deliver unique energy therapy to control BP. The second product is BP-ADJUST™ CV. This device uses the same technology, plus additional features that monitor vital diagnostic information, such as heart rate variability, ECG, heart arrhythmia, and oxygen level in combination with BP. The system is completely battery-operated, with rechargeable capabilities and wireless data communication.
BP-ADJUST™ and BP-ADJUST™ CV will be first-to-market devices of their kind to monitor and treat patients. Shawn Moaddeb says, “Our technology is truly unique, and it will be an absolute breakthrough as preventive therapy for prehypertensive patients and when used in combination with drugs in treating uncontrolled hypertension.”
Reza Allamehzadeh, M.D., chief medical officer at Pressao Medical and a hypertension and nephrology specialist says, “Overall prevalence of prehypertension in healthy adults is about 36% worldwide. Prehypertension, by itself, increases risk of heart disease by more than twofold. Prehypertensive patients have a 31% increased risk of coronary heart disease, 49% greater risk of stroke, and 44% greater risk of total cardiovascular events. By current guidelines, lifestyle modification is pursued over pharmacologic treatment (as currently there are no approved drugs for prehypertension) which may not completely lower the above risks. Reducing BP, even a few points, can make a significant impact.”
